No connection

Search Results

ANIP vs UFPT

ANIP
ANI Pharmaceuticals, Inc.
BEARISH
Price
$70.49
Market Cap
$1.58B
Sector
Healthcare
AI Confidence
85%
UFPT
UFP Technologies, Inc.
NEUTRAL
Price
$198.68
Market Cap
$1.53B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ANIP
21.23
UFPT
22.71
Forward P/E
ANIP
6.82
UFPT
17.35
P/B Ratio
ANIP
2.73
UFPT
3.62
P/S Ratio
ANIP
1.79
UFPT
2.54
EV/EBITDA
ANIP
10.33
UFPT
14.86

Profitability

Gross Margin
ANIP
61.36%
UFPT
28.27%
Operating Margin
ANIP
11.99%
UFPT
14.1%
Profit Margin
ANIP
8.87%
UFPT
11.33%
ROE
ANIP
16.16%
UFPT
17.82%
ROA
ANIP
3.82%
UFPT
9.05%

Growth

Revenue Growth
ANIP
29.6%
UFPT
3.4%
Earnings Growth
ANIP
--
UFPT
6.8%

Financial Health

Debt/Equity
ANIP
1.16
UFPT
0.36
Current Ratio
ANIP
2.71
UFPT
2.69
Quick Ratio
ANIP
2.07
UFPT
1.45

Dividends

Dividend Yield
ANIP
--
UFPT
--
Payout Ratio
ANIP
0.0%
UFPT
0.0%

AI Verdict

ANIP BEARISH

ANIP's Piotroski F-Score of 4/9 indicates weak financial health, falling short of the stable threshold and signaling potential operational inefficiencies. The absence of an Altman Z-Score raises concern about bankruptcy risk, especially given a high debt/equity ratio of 1.16. Despite strong revenue growth (29.6% YoY) and solid gross margins (61.36%), the stock trades at a premium to its intrinsic value, with a current price of $70.49 versus a Graham Number of $43.90 and intrinsic value of $23.24. Insider selling activity totaling $3.39M in the last six months further undermines confidence, while technical trends remain bearish. Analysts remain optimistic with a $110.62 target, but this may reflect overvaluation given the underlying financial and sentiment risks.

Strengths
Strong revenue growth of 29.6% YoY
High gross margin of 61.36%
Solid operating margin of 11.99%
Risks
Piotroski F-Score of 4/9 indicates weak financial health
No Altman Z-Score available, raising potential bankruptcy risk
Insider selling activity totaling $3.39M in last 6 months
UFPT NEUTRAL

UFPT exhibits exceptional fundamental health with a perfect Piotroski F-Score of 9/9 and a very conservative debt profile. However, the stock is currently trading at a significant premium, with a current price of $198.68 well above its Graham Number ($104.01) and Intrinsic Value ($150.50). While the earnings track record is stellar, organic growth is sluggish at 1.5%, and high customer concentration (45.8% from two clients) presents a systemic risk. The combination of a high PEG ratio (3.80) and bearish insider activity suggests the stock is currently overvalued despite its operational excellence.

Strengths
Perfect Piotroski F-Score (9/9) indicating peak financial health
Strong liquidity with a Current Ratio of 2.69 and low Debt/Equity of 0.36
Exceptional earnings track record with consistent beats over 25 quarters
Risks
Severe customer concentration: Intuitive Surgical and Stryker account for 45.8% of sales
Weak organic growth (1.5%) suggesting reliance on acquisitions for top-line expansion
High valuation relative to growth (PEG Ratio of 3.80)

Compare Another Pair

ANIP vs UFPT: Head-to-Head Comparison

This page compares ANI Pharmaceuticals, Inc. (ANIP) and UFP Technologies, Inc. (UFPT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile